ReCor presents data for Paradise hypertension renal denervation system

Paradise catheter
Paradise catheter

ReCor Medical has reported six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the company’s Paradise system. According to a company release, this is the only system for renal denervation that is based on ultrasound, not radiofrequency, energy.

At six months follow-up, the Paradise data showed that office systolic blood pressure was reduced by an average of 33mm Hg in 8 patients. There were also significant and sustained blood pressure reductions in home and ambulatory measurements at six months. The scientific literature demonstrates that only a 5mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.


“These clinical results strongly suggest a significant competitive advantage for ReCor’s ultrasound-based Paradise system compared to radiofrequency-based standard of care for treating resistant hypertension patients,” said Mano Iyer, CEO, ReCor Medical.

The Paradise ultrasound catheter was designed with the aim to allow complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency ablation catheter. The procedure with the Paradise system only requires 30 seconds of energy delivery per treatment location, thereby dramatically reducing the overall procedure time.